论文信息 - Clinical Characteristics and Outcome for Four SARS-CoV-2-infected Cancer Patients Treated with Immune Checkpoint Inhibitors - 字舞流文

Clinical Characteristics and Outcome for Four SARS-CoV-2-infected Cancer Patients Treated with Immune Checkpoint Inhibitors

T. Powles | A. Bex | Y. Abu-Ghanem | B. Szabados | J. Choy | M. Grant

[1] T. Powles,et al. Advice Regarding Systemic Therapy in Patients with Urological Cancers During the COVID-19 Pandemic , 2020, European Urology.

[2] C. Wang,et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China , 2020, Annals of Oncology.

[3] M. Chua,et al. SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China , 2020, JAMA oncology.

[4] J. Xiang,et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[5] Ruchong Chen,et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China , 2020, The Lancet Oncology.

[6] C. Robert,et al. Post-shingles granulomatous dermatosis related to anti-programmed cell death 1. , 2019, Immunotherapy.

[7] Emily C. Zhu,et al. Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis , 2019, Front. Immunol..

[8] Matthew D. Hellmann,et al. Immune‐Related Adverse Events Associated with Immune Checkpoint Blockade , 2018, The New England journal of medicine.